Skip to content

Values of hyaluronic acid in evaluating the severity and prognosis of patients with coronavirus disease 2019:A multicenter retrospective cohort study

Values of hyaluronic acid in evaluating the severity and prognosis of patients with coronavirus disease 2019:A multicenter retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071068
Enrollment
Unknown
Registered
2023-05-04
Start date
2023-05-04
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus disease 2019

Interventions

Sponsors

Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School (The First people’s Hospital of Yancheng)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) All patients who meet the standards of the National Health Commission's "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)" and are positive for novel coronavirus nucleic acid according to reverse transcription polymerase chain reaction (RT-PCR) and are clearly diagnosed with COVID-19; (2) COVID-19 patients with complete examinations, test results, disease course records, and doctor's orders; (3) Age> 18 years old.

Exclusion criteria

Exclusion criteria: (1) At the time of admission, chronic heart and lung diseases, such as chronic obstructive pulmonary disease, pulmonary fibrosis, interstitial lung disease, tuberculosis, etc., were already present; (2) Previously suffering from diseases that can affect blood routine and hyaluronic acid test structure, such as cirrhosis, liver function damage, uremia, hematological diseases, malignant tumors, etc; (3) Pregnant women and those with positive urine pregnancy test;(4) The clinical case data of the patient is incomplete.

Design outcomes

Primary

MeasureTime frame
28-day mortality;90-day mortality;

Secondary

MeasureTime frame
Rate of tracheal intubation ;Duration of mechanical ventilation;Length of ICU stay;

Countries

China

Contacts

Public ContactGen hua Mu

Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School (The First people’s Hospital of Yancheng)

mugenhua2009@163.com+86 1381554925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026